Provided by Tiger Fintech (Singapore) Pte. Ltd.

STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD

27.38
-0.1800-0.65%
Post-market: 27.380.00000.00%19:39 EDT
Volume:510.89K
Turnover:14.09M
Market Cap:1.58B
PE:-8.78
High:28.56
Open:27.06
Low:27.00
Close:27.56
52wk High:42.57
52wk Low:13.22
Shares:57.60M
Float Shares:44.53M
Volume Ratio:0.47
T/O Rate:1.15%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1192
EPS(LYR):-2.3276
ROE:-21.14%
ROA:-15.57%
PB:2.04
PE(LYR):-11.76

Loading ...

Structure Therapeutics (GPCR): Assessing Valuation After Recent Share Price Surge

Simply Wall St.
·
Oct 12

Press Release: Septerna Appoints Veteran Biotechnology Leader Keith Gottesdiener, M.D., to its Board of Directors

Dow Jones
·
Sep 30

Cantor Fitzgerald Sticks to Its Buy Rating for Structure Therapeutics, Inc. Sponsored ADR (GPCR)

TIPRANKS
·
Sep 17

Structure Therapeutics, Inc. Sponsored ADR (GPCR) Gets a Buy from LifeSci Capital

TIPRANKS
·
Sep 16

Structure Therapeutics Inc. to Participate in Cantor Global Healthcare Conference

Reuters
·
Sep 02

Septerna to Participate in Upcoming Investor Conferences

GlobeNewswire
·
Aug 27

Septerna Highlights Business Progress and Reports Second Quarter 2025 Financial Results

GlobeNewswire
·
Aug 12

Structure Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

Reuters
·
Aug 08

Structure Therapeutics Inc : H.c. Wainwright Cuts Target Price to $60 From $75

THOMSON REUTERS
·
Aug 07

Structure Therapeutics : Sales Agreement Prospectus Covers Offering of up to $250 Mln Adss Representing Ordinary Shares

THOMSON REUTERS
·
Aug 07

Structure Therapeutics Q2 EPS $(0.36) Misses $(0.25) Estimate

Benzinga
·
Aug 07

Structure Therapeutics Inc - Holds $786.5 Mln in Cash and Investments as of June 30 - SEC Filing

THOMSON REUTERS
·
Aug 07

Structure Therapeutics Inc - Accg-2671 Phase 1 Study to Start by Year-End 2025

THOMSON REUTERS
·
Aug 07

Structure Therapeutics Inc - Has $786.5 Mln Cash to Fund Operations Through 2027

THOMSON REUTERS
·
Aug 07

Structure Therapeutics Inc. Q2 Operating Expenses USD 70.451 Million

THOMSON REUTERS
·
Aug 07

Structure Therapeutics Inc - Aleniglipron Access Studies Data Expected by Year-End 2025

THOMSON REUTERS
·
Aug 07

Structure Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights

THOMSON REUTERS
·
Aug 07

Structure Therapeutics Inc expected to post a loss of 28 cents a share - Earnings Preview

Reuters
·
Aug 05

Structure Therapeutics Inc. Concluded Annual Shareholders' Meeting

Reuters
·
Jun 26

Structure Therapeutics Inc. Unveils Promising Preclinical Data for Oral Small Molecule Amylin Agonist ACCG-2671 at ADA Scientific Sessions

Reuters
·
Jun 21